A dose of immunity during a market downturn
Accelerating innovation in the biotechnology sector may offer investors new potential growth opportunities. In a market environment where we believe investors should tread carefully, Jennifer Nichols, Client Portfolio Manager and Matthew Bullock, EMEA Head of Portfolio Construction and Strategy discussed how healthcare’s unique blend of defensive characteristics and growth potential may offer immunity from the downturn.
30 minute watch
These are the views of the author at the time of publication and may differ from the views of other individuals/teams at Janus Henderson Investors. Any securities, funds, sectors and indices mentioned within this article do not constitute or form part of any offer or solicitation to buy or sell them.
Past performance does not predict future returns. The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
The information in this article does not qualify as an investment recommendation.